

Monica Marta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5012216/publications.pdf>

Version: 2024-02-01

62
papers

3,282
citations

304602

22
h-index

149623

56
g-index

82
all docs

82
docs citations

82
times ranked

4612
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple Sclerosis Severity Score. <i>Neurology</i> , 2005, 64, 1144-1151.	1.5	836
2	Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 329-333.	0.9	275
3	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
4	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. <i>EBioMedicine</i> , 2017, 16, 41-50.	2.7	225
5	T Cell Ig- and Mucin-Domain-Containing Molecule-3 (TIM-3) and TIM-1 Molecules Are Differentially Expressed on Human Th1 and Th2 Cells and in Cerebrospinal Fluid-Derived Mononuclear Cells in Multiple Sclerosis. <i>Journal of Immunology</i> , 2004, 172, 7169-7176.	0.4	200
6	Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2008, 38, 565-575.	1.6	180
7	Myasthenia gravis and neuromyelitis optica spectrum disorder. <i>Neurology</i> , 2012, 78, 1601-1607.	1.5	177
8	A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. <i>Neurology</i> , 2011, 77, 1551-1560.	1.5	118
9	No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e158.	3.1	109
10	The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102279.	0.9	77
11	Regulation of autoimmune encephalomyelitis by toll-like receptors. <i>Autoimmunity Reviews</i> , 2009, 8, 506-509.	2.5	69
12	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	1.5	58
13	Toll-like Receptors in Multiple Sclerosis Mouse Experimental Models. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 458-462.	1.8	53
14	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression. <i>PLoS ONE</i> , 2013, 8, e70019.	1.1	48
15	Protecting people with multiple sclerosis through vaccination. <i>Practical Neurology</i> , 2020, 20, 435.1-445.	0.5	40
16	The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population. <i>Journal of the Neurological Sciences</i> , 2007, 258, 69-74.	0.3	39
17	Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. <i>Practical Neurology</i> , 2016, 16, 389-393.	0.5	39
18	Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats. <i>Neurobiology of Disease</i> , 2014, 71, 220-233.	2.1	34

#	ARTICLE	IF	CITATIONS
19	Alemtuzumab depletion failure can occur in multiple sclerosis. <i>Immunology</i> , 2018, 154, 253-260.	2.0	32
20	Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 610-623.	0.8	29
21	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 123-128.	0.9	25
22	Resolution of a 16.8-Mb Autoimmunity-Regulating Rat Chromosome 4 Region into Multiple Encephalomyelitis Quantitative Trait Loci and Evidence for Epistasis. <i>Journal of Immunology</i> , 2005, 174, 918-924.	0.4	24
23	Fine-Mapping Resolves Eae23 into Two QTLs and Implicates ZEB1 as a Candidate Gene Regulating Experimental Neuroinflammation in Rat. <i>PLoS ONE</i> , 2010, 5, e12716.	1.1	23
24	Development of resistance to biologic therapies with reference to IFN- β . <i>Rheumatology</i> , 2012, 51, 590-599.	0.9	22
25	Multiple loci comprising immune-related genes regulate experimental neuroinflammation. <i>Genes and Immunity</i> , 2010, 11, 21-36.	2.2	20
26	Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. <i>Pathophysiology</i> , 2011, 18, 13-20.	1.0	19
27	Advanced Intercross Line Mapping Suggests That Ncf1 (Ean6) Regulates Severity in an Animal Model of Guillain-Barré Syndrome. <i>Journal of Immunology</i> , 2009, 182, 4432-4438.	0.4	18
28	The role of infections in Behçet disease and neuro-Behçet syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 609-615.	2.5	18
29	Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complex. <i>Arthritis and Rheumatism</i> , 2008, 58, 1343-1353.	6.7	15
30	TNF Production in Macrophages Is Genetically Determined and Regulates Inflammatory Disease in Rats. <i>Journal of Immunology</i> , 2010, 185, 442-450.	0.4	14
31	A whole genome association study in multiple sclerosis patients from north Portugal. <i>Journal of Neuroimmunology</i> , 2003, 143, 116-119.	1.1	13
32	Eae19, a New Locus on Rat Chromosome 15 Regulating Experimental Autoimmune Encephalomyelitis. <i>Genetics</i> , 2005, 170, 283-289.	1.2	13
33	Visibility and representation of women in multiple sclerosis research. <i>Neurology</i> , 2019, 92, 713-719.	1.5	13
34	Deep Sequencing of HIV-1 in Cerebrospinal Fluid: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 1022-1025.	2.9	12
35	CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, e880.	3.1	12
36	Hypersomnia in Whipple disease: case report. <i>Arquivos De Neuro-Psiquiatria</i> , 2006, 64, 865-868.	0.3	11

#	ARTICLE	IF	CITATIONS
37	Anti-MOG antibodies are under polygenic regulation with the most significant control coming from the C-type lectin-like gene locus. <i>Genes and Immunity</i> , 2013, 14, 409-419.	2.2	11
38	Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. <i>BMC Neurology</i> , 2014, 14, 237.	0.8	11
39	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 247-253.	0.9	10
40	Serum neurofilament-light concentration and real-world outcome in MS. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117079.	0.3	10
41	Cognitive and Neurologic Rehabilitation Strategies for Central Nervous System HIV Infection. <i>Current HIV/AIDS Reports</i> , 2020, 17, 514-521.	1.1	10
42	IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. <i>Practical Neurology</i> , 2016, 16, 235-239.	0.5	9
43	Disease modification in advanced MS: Focus on upper limb function. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1956-1957.	1.4	8
44	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , 2021, 35, 2341-2346.	1.0	8
45	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731878376.	0.5	7
46	Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 172-176.	0.9	6
47	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102024.	0.9	6
48	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110576.	1.5	5
49	Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 88-91.	0.9	4
50	Recurrent cerebrospinal fluid escape in an HIV-1-infected patient receiving antiretroviral therapy. <i>Aids</i> , 2016, 30, 1143-1144.	1.0	4
51	Inclusion criteria used in trials of people with progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 279-283.	1.4	3
52	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. <i>BMJ Open</i> , 2021, 11, e050176.	0.8	3
53	Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e74.	3.1	2
54	PO134 Personalised dosing of cladribine to treat multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A47.4-A48.	0.9	1

#	ARTICLE	IF	CITATIONS
55	No evidence of disease activity in people with multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 1-2.	1.7	1
56	Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103284.	0.9	1
57	Epstein-Barr Virus and Multiple Sclerosis. , 2011, , 25-37.		1
58	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103409.	0.9	1
59	Vitamin D deficiency "do we follow our own advice?. <i>Clinical Medicine</i> , 2011, 11, 521-523.	0.8	0
60	PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A44.3-A45.	0.9	0
61	PO150 Memory b cells are key for immunotherapy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A52.2-A52.	0.9	0
62	Personalised immunotherapy in active multiple sclerosis using injectable cladribine: Follow-up of the BartsMS cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A2.3-A2.	0.9	0